代谢功能障碍相关脂肪性肝病与2型糖尿病及心血管并发症相关性研究进展

doi:10.12114/j.issn.1007-9572.2024.0613

中国全科医学 ›› 2026, Vol. 29 ›› Issue (09): 1212-1216.DOI: 10.12114/j.issn.1007-9572.2024.0613

所属专题：心血管最新文章合辑

• 综述与专论 • 上一篇

代谢功能障碍相关脂肪性肝病与2型糖尿病及心血管并发症相关性研究进展

黄颖¹, 周智远¹, 潘志雄², 祝群¹^,^*()

1．210011　江苏省南京市，南京医科大学第二附属医院内分泌科
2．541001　广西壮族自治区桂林市，桂林医学院附属医院广西肝脏损伤与修复分子医学重点实验室

收稿日期:2024-11-04 修回日期:2025-01-16 出版日期:2026-03-20 发布日期:2026-01-28
通讯作者: 祝群
作者贡献：
黄颖负责文章的构思与设计、论文撰写；周智远负责制订检索策略、收集与整理文献；潘志雄负责论文的修订；祝群负责文章的质量控制及审校，并对文章整体负责；所有作者确认了论文的最终稿。
基金资助:
广西肝脏损伤与修复分子医学重点实验室子课题(GXLIRMMKL-K202001)

Advances in the Association between Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus and Cardiovascular Complications

HUANG Ying¹, ZHOU Zhiyuan¹, PAN Zhixiong², ZHU Qun¹^,^*()

1. Department of Endocrinology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China
2. Key Laboratory of Molecular Medicine in Liver Injury and Repair, Affiliated Hospital of Guilin Medical University, Guilin 541001, China

Received:2024-11-04 Revised:2025-01-16 Published:2026-03-20 Online:2026-01-28
Contact: ZHU Qun

分享到

摘要/Abstract

摘要： 代谢功能障碍相关脂肪性肝病（MASLD）与2型糖尿病（T2DM）存在密切关联。MASLD及其引起的肝纤维化一方面通过诱导胰岛素抵抗和直接影响肝糖原合成促进T2DM的发生、进展；另一方面，通过胰岛素抵抗引起的血管内皮因子异常、血脂异常及诱导高凝状态显著增加了T2DM患者心血管并发症的发生风险和死亡率。在药物治疗方面，一些多靶点的新型降糖药物不仅能够有效减少肝内脂质沉积，改善肝脏血清学指标，而且对于延缓肝纤维化进展也具有潜在价值。本文综述了MASLD及肝纤维化与T2DM及心血管并发症发生的相关性、机制和药物治疗方面的研究进展，以期为T2DM合并MASLD患者的临床诊疗提供新的思路。

Abstract:

Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely associated with type 2 diabetes mellitus (T2DM). MASLD and its associated liver fibrosis contribute to the onset and progression of T2DM through the induction of insulin resistance and direct disruption of hepatic glycogen synthesis. Additionally, MASLD significantly elevates cardiovascular risk and mortality in patients with T2DM, mediated by abnormality of vascular endothelial factors and dyslipidemia resulting from insulin resistance, as well as hypercoagulability. In terms of pharmacological treatment, certain novel multi-target hypoglycemic agents have been proven to be efficacious in reducing intrahepatic lipid deposition and improving liver enzyme levels, while also having the potential to mitigate the progression of liver fibrosis. Altogether, this article reviews the association, mechanism and pharmacological treatment of MASLD and its associated liver fibrosis with T2DM and its cardiovascular complications, aiming to provide novel insights for the clinical diagnosis and treatment of patients with T2DM and MASLD.

Key words: Metabolic dysfunction-associated steatotic liver disease, Liver fibrosis, Type 2 diabetes mellitus, Cardiovascular complications, Treatment

黄颖,周智远,潘志雄,等. 代谢功能障碍相关脂肪性肝病与2型糖尿病及心血管并发症相关性研究进展[J]. 中国全科医学, 2026, 29(09): 1212-1216. DOI: 10.12114/j.issn.1007-9572.2024.0613.
HUANG Ying,ZHOU Zhiyuan,PAN Zhixiong, et al. Advances in the Association between Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus and Cardiovascular Complications[J]. Chinese General Practice, 2026, 29(09): 1212-1216. DOI: 10.12114/j.issn.1007-9572.2024.0613.

参考文献 32

[1]	RIAZI K, AZHARI H, CHARETTE J H, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7(9): 851-861. DOI: 10.1016/S2468-1253(22)00165-0.
[2]	KUMAR V, XIN X F, MA J Y, et al. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis[J]. Adv Drug Deliv Rev, 2021, 176: 113888. DOI: 10.1016/j.addr.2021.113888.
[3]	STEFAN N, CUSI K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes[J]. Lancet Diabetes Endocrinol, 2022, 10(4): 284-296. DOI: 10.1016/S2213-8587(22)00003-1.
[4]	CAO L M, AN Y, LIU H Y, et al. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis[J]. BMC Med, 2024, 22(1): 101. DOI: 10.1186/s12916-024-03315-0.
[5]	SEO I H, LEE H S, LEE Y J. Fatty liver index as a predictor for incident type 2 diabetes in community-dwelling adults: longitudinal findings over 12 years[J]. Cardiovasc Diabetol, 2022, 21(1): 209. DOI: 10.1186/s12933-022-01642-1.
[6]	PARK K Y, PARK J H, HAN K, et al. Fatty liver change in older adults as an important risk factor for type 2 diabetes: a nationwide cohort study[J]. Mayo Clin Proc, 2023, 98(12): 1809-1819. DOI: 10.1016/j.mayocp.2023.02.033.
[7]	YANG J D, AHMED F, MARA K C, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease[J]. Hepatology, 2020, 71(3): 907-916. DOI: 10.1002/hep.30858.
[8]	GENG Y N, FABER K N, DE MEIJER V E, et al. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?[J]. Hepatol Int, 2021, 15(1): 21-35. DOI: 10.1007/s12072-020-10121-2.
[9]	MEEX R C R, WATT M J. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance[J]. Nat Rev Endocrinol, 2017, 13(9): 509-520. DOI: 10.1038/nrendo.2017.56.
[10]	STERN J H, RUTKOWSKI J M, SCHERER P E. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk[J]. Cell Metab, 2016, 23(5): 770-784. DOI: 10.1016/j.cmet.2016.04.011.
[11]	LEE W H, NAJJAR S M, KAHN C R, et al. Hepatic insulin receptor: new views on the mechanisms of liver disease[J]. Metabolism, 2023, 145: 155607. DOI: 10.1016/j.metabol.2023.155607.
[12]	WAN Y J, HU Z X, LIU Q H, et al. Liver fibrosis alters the molecular structures of hepatic glycogen[J]. Carbohydr Polym, 2022, 278: 118991. DOI: 10.1016/j.carbpol.2021.118991.
[13]	BOURSIER J, ANTY R, CARETTE C, et al. Management of diabetes mellitus in patients with cirrhosis: an overview and joint statement[J]. Diabetes Metab, 2021, 47(5): 101272. DOI: 10.1016/j.diabet.2021.101272.
[14]	KIM K S, HONG S M, HAN K, et al. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study[J]. BMJ, 2024, 384: e076388. DOI: 10.1136/bmj-2023-076388.
[15]	PARK J, KIM G, KIM B S, et al. The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: a nationwide cohort study[J]. Diabetes Res Clin Pract, 2022, 194: 110191. DOI: 10.1016/j.diabres.2022.110191.
[16]	DUAN W F, SHI R X, YANG F, et al. FSTL3 partially mediates the association of increased nonalcoholic fatty liver disease fibrosis risk with acute myocardial infarction in patients with type 2 diabetes mellitus[J]. Cardiovasc Diabetol, 2023, 22(1): 297. DOI: 10.1186/s12933-023-02024-x.
[17]	LOMBARDI R, AIRAGHI L, TARGHER G, et al. Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes[J]. Liver Int, 2020, 40(2): 347-354. DOI: 10.1111/liv.14274.
[18]	MIKOLASEVIC I, RAHELIC D, TURK-WENSWEEN T, et al. Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: a multicenter study[J]. Diabetes Res Clin Pract, 2021, 177: 108884. DOI: 10.1016/j.diabres.2021.108884.
[19]	CARDOSO C R L, VILLELA-NOGUEIRA C A, LEITE N C, et al. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study[J]. Cardiovasc Diabetol, 2021, 20(1): 193. DOI: 10.1186/s12933-021-01388-2.
[20]	YE J Z, ZHUANG X D, LI X, et al. Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: a data-driven cluster analysis with international validation[J]. Metabolism, 2022, 136: 155294. DOI: 10.1016/j.metabol.2022.155294.
[21]	HILL M A, YANG Y, ZHANG L P, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease[J]. Metabolism, 2021, 119: 154766. DOI: 10.1016/j.metabol.2021.154766.
[22]	CASTILLO-NÚÑEZ Y, ALMEDA-VALDES P, GONZÁLEZ-GÁLVEZ G, et al. Metabolic dysfunction-associated steatotic liver disease and atherosclerosis[J]. Curr Diab Rep, 2024, 24(7): 158-166. DOI: 10.1007/s11892-024-01542-6.VALENTIL,
[23]	TRIPODI A, MURA V L, et al. Clinical and genetic determinants of the fatty liver-coagulation balance interplay in individuals with metabolic dysfunction[J]. JHEP Rep, 2022, 4(12): 100598. DOI: 10.1016/j.jhepr.2022.100598.
[24]	BOCCATONDA A, DEL CANE L, MAROLA L, et al. Platelet, antiplatelet therapy and metabolic dysfunction-associated steatotic liver disease: a narrative review[J]. Life, 2024, 14(4): 473. DOI: 10.3390/life14040473.
[25]	DOKMAK A, ALMEQDADI M, TRIVEDI H, et al. Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease[J]. World J Hepatol, 2019, 11(7): 562-573. DOI: 10.4254/wjh.v11.i7.562.
[26]	DEEKS E D. Chiglitazar: first approval[J]. Drugs, 2022, 82(1): 87-92. DOI: 10.1007/s40265-021-01648-1.
[27]	EZHILARASAN D. Deciphering the molecular pathways of saroglitazar: a dual PPAR α/γ agonist for managing metabolic NAFLD[J]. Metabolism, 2024, 155: 155912. DOI: 10.1016/j.metabol.2024.155912.
[28]	RATZIU V, FRANCQUE S, BEHLING C A, et al. Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis[J]. Hepatology, 2024, 80(1): 173-185. DOI: 10.1097/HEP.0000000000000723.
[29]	MOON J S, HONG J H, JUNG Y J, et al. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease[J]. Trends Endocrinol Metab, 2022, 33(6): 424-442. DOI: 10.1016/j.tem.2022.03.005.
[30]	LOOMBA R, HARTMAN M L, LAWITZ E J, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis[J]. N Engl J Med, 2024, 391(4): 299-310. DOI: 10.1056/NEJMoa2401943.
[31]	SAMMS R J, COGHLAN M P, SLOOP K W. How may GIP enhance the therapeutic efficacy of GLP-1?[J]. Trends Endocrinol Metab, 2020, 31(6): 410-421. DOI: 10.1016/j.tem.2020.02.006.
[32]	SHEN Y F, CHENG L D, XU M X, et al. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis[J]. Metabolism, 2023, 146: 155657. DOI: 10.1016/j.metabol.2023.155657.

代谢功能障碍相关脂肪性肝病与2型糖尿病及心血管并发症相关性研究进展

Advances in the Association between Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus and Cardiovascular Complications

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 32

相关文章 15

编辑推荐

Metrics

留言

[1]	赵倩倩, 张梅, 李艳英, 张艳红, 晏文华, 潘慧, 班博. 生长激素缺乏症的临床特征与重组人生长激素疗效分析：一项十年纵向队列研究[J]. 中国全科医学, 2026, 29(06): 733-740.
[2]	张彦景, 周春华, 李晓东, 刘琰, 王婧, 于静. 文拉法辛血药浓度超警戒值风险预测模型的临床价值研究[J]. 中国全科医学, 2026, 29(06): 777-782.
[3]	梁灵君, 张军, 陈建辉, 高永双. 2022—2024年利培酮治疗药物监测结果的回顾性分析[J]. 中国全科医学, 2026, 29(06): 783-789.
[4]	杨海飞, 孙武, 吴成, 任伟, 李茹恬. 进展期食管鳞状细胞癌免疫相关不良反应的预测因素及其与疗效相关性分析[J]. 中国全科医学, 2026, 29(06): 710-717.
[5]	王艺衡, 许晓明, 夏云龙, 夏林莺, 韩雪, 郭永珍, 刘泉池, 闫文俊. 射血分数保留的心力衰竭药物治疗进展[J]. 中国全科医学, 2026, 29(03): 403-408.
[6]	马腾腾, 诸秉根. "全-专"分级精准管理对2型糖尿病低血糖的防治效应：一项随机对照研究[J]. 中国全科医学, 2026, 29(03): 331-339.
[7]	中华医学会心身医学分会心身内分泌协作学组, 中华预防医学会糖尿病预防与控制专业委员会. 糖尿病共患抑郁诊疗中国专家共识[J]. 中国全科医学, 2026, 29(03): 273-292.
[8]	马玉萍, 乔梦媛, 何雁云, 徐曼如, 陈崇利, 伍文彬. "体病相关"视角下探析老年2型糖尿病伴轻度认知障碍现状及影响因素研究：以四川省为例[J]. 中国全科医学, 2026, 29(02): 188-194.
[9]	陈丽, 熊卫红, 路孝琴. 经皮冠状动脉介入术后患者用药依从性及影响因素研究[J]. 中国全科医学, 2025, 28(36): 4586-4591.
[10]	范学明, 杨宁宁, 郑症, 吴玉梅, 王祺. 2型糖尿病合并代谢相关脂肪性肝病患者微血管病变发生的相关因素分析及预测价值研究[J]. 中国全科医学, 2025, 28(36): 4578-4585.
[11]	邵家琛, 李顺平, 杨汀, 张春瑜, 路立勇, 袁佳麒. 利用离散选择试验测量慢性阻塞性肺疾病患者治疗与装置偏好的综述[J]. 中国全科医学, 2025, 28(36): 4648-4654.
[12]	曾明慧, 蒯文涛, 陈林, 韩家鑫, 徐连欣, 葛立颖, 代容容, 宓余强, 徐亮. 2型糖尿病对核苷（酸）类似物治疗慢性乙型肝炎效果的影响研究[J]. 中国全科医学, 2025, 28(35): 4414-4420.
[13]	霍兴霄, 孙松朋, 龙俊红, 梁隆雨, 褚洪川, 周阳洋, 刘彦, 刘甲鑫. 痔的注射治疗在中国的应用现状调查研究[J]. 中国全科医学, 2025, 28(35): 4435-4441.
[14]	徐君, 张劼. 2型糖尿病患者心率变异性与脑梗死的相关性研究[J]. 中国全科医学, 2025, 28(35): 4409-4413.
[15]	严明, 董佳惠, 陆益婷, 赵洋, 方力争, 徐志杰. 社区残疾人慢性病共病治疗负担现状及其影响因素研究[J]. 中国全科医学, 2025, 28(32): 4015-4023.